Vulvovaginal Candidiasis Treatment Market (By Drug Type: Clotrimazole, Nystatin, Fluconazole; By Route Of Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Vulvovaginal Candidiasis (VVC) is one of the most common infections among women, affecting around 138 million women annually worldwide. Globally, vulvovaginal candidiasis affects about 75% of women, with at least one incidence over a lifetime. It is estimated that approximately 10%-20% of women suffer from complicated VVC. In addition, recurrent VVC prevalence is rising, affecting more than 9% of women annually. In recent years, VVC prevalence has increased due to growing diabetes cases and repeated antibiotic usage among individuals. About 15% of women in all these cases require special therapeutic considerations. All these factors raise the demand for effective therapeutics, thereby creating lucrative opportunities for market players. 

Global players are strategically addressing the market need by engaging in the R&D of new drugs and product launches. For instance, in August 2022, Mycovia Pharmaceuticals’ received FDA approval for VIVJOA (Oral small-molecule selective fungal CYP51 inhibitor) in the U.S. It is the first approved drug for treating recurrent VVC in females, before the U.S. this drug was already approved in some European, Asian, Latin American countries. Furthermore, emerging novel drug therapies are expected to boost treatment options. For instance, in June 2021, FDA approved, Scynexis, Inc.’s Brexafemme (Ibrexafungerp), a novel drug class used to treat vulvovaginal candidiasis. The subsequent launch of these drugs over the coming years is expected to accelerate market growth. 

In the market, the route of administration segment has been sub-segmented as:

  • Oral
  • Intravenous
  • Topical 

The space has a substantial presence of over-the-counter intravaginal agents for treating mild to moderate conditions. This includes products such as clotrimazole cream, miconazole cream, and tioconazole ointment. These products are recommended as first-line therapies for the disease indication. In addition, the demand for prescription products is also rising due to growing moderate to severe disease cases; some of the popular prescription products include butoconazole cream, terconazole cream, and fluconazole oral drugs. Long-duration therapy of oral fluconazole is recommended for initial therapy and maintenance regime for complicated VVC. Other treatment options include Echinocandins (caspofungin, micafungin) and amphotericin B deoxycholate, administered through IV and infusion. 

The recent advancement in vulvovaginal candidiasis space, such as immunopathology, inflammasome, the role of candidalysin, and PRR-mediated signaling at the vaginal mucosa, have opened multiple opportunities for new drug development and treatment options. 

Key Players

  • Astellas Pharma Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Basilea Pharmaceutica Ltd.
  • Scynexis, Inc.
  • Grupo Ferrer Internacional, S.A.
  • Pfizer, Inc.

Market Segmentation

  • By drug class
    •  Clotrimazole
    • Nystatin
    • Fluconazole
    • Ketoconazole
    • Terbinafine
    • Terconazole
    • Others
  • By route of administration
    • Oral
    • Intravenous
    • Topical
  • By distribution channel
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • By region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East Asia

Report Detail

Proceed To Buy

USD 3500
USD 7000